Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
about
Antisense mediated splicing modulation for inherited metabolic diseases: challenges for deliveryBrief suppression of Abcc8 prevents autodestruction of spinal cord after traumaTherapeutics development in myotonic dystrophy type 1.Oligonucleotide-based strategies to combat polyglutamine diseases.MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-terminal kinase pathwaySuperior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense InhibitorsDevelopment of Antisense Drugs for Dyslipidemia.Myotonic dystrophy mouse models: towards rational therapy development.Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.Canonical and non-canonical barriers facing antimiR cancer therapeuticsBarriers to Liposomal Gene Delivery: from Application Site to the Target.Biodistribution of antisense nanoparticles in mammary carcinoma rat model.Maximization of loading and stability of ssDNA:iron oxide nanoparticle complexes formed through electrostatic interaction.Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease.Assessing the Off-Target Effects of miRNA Inhibitors on Innate Immune Toll-Like Receptors.Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer.Structural Determinants for the Interactions of Chemically Modified Nucleic Acids with the Stabilin-2 Clearance Receptor.
P2860
Q26830637-D091D99B-2EF4-4A75-9577-F8F39661D980Q30273785-0BE0ECEE-5B3D-4AEF-98A6-DE29EB078383Q30425796-CB33BEAD-5593-47E3-91FC-C639CC5DEECAQ33791247-E9062516-C03F-4735-898D-20E37081C329Q35201318-1C625213-C407-4D6E-B38E-990F5B4A8AA4Q36085047-89940794-0B65-49B2-A090-6172DF7595C3Q36296557-CE0A7F1C-1BC9-435D-92F7-8088E5200848Q37387192-4E86586F-45F9-4BB7-AE3F-45EED7CFA5E9Q37434343-F5489B6E-F114-43CA-BDEF-24F1F773EA7FQ37734660-0839C66E-B89A-4C27-999F-9CF768D0BFD0Q38085679-A100B264-BA1C-4917-9A4C-967451A05539Q38112723-BFDA5327-4E7C-4029-A2F4-FC57C4C2EC62Q39147224-14BC467F-919A-4F05-A07A-4C79AA4B35EBQ39709283-5A68EE76-6FF6-4406-A86A-DC86A1D5EDE0Q41357194-68169E1F-7BF2-4140-AEC8-D0158BB07883Q50130748-2C252BD1-449C-4645-854A-F625E5ED6198Q51282064-2D45E2C7-8997-439A-9865-A430E7A7399BQ55223926-E3B9D9E8-79D5-472D-A55C-A4D2EE0AE701Q55375711-61A9E786-DF97-4AA6-92C1-1350E6A70BC7
P2860
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
@en
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
@nl
type
label
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
@en
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
@nl
prefLabel
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
@en
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
@nl
P2860
P1476
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides
@en
P2093
Frank Anastasopoulos
Paul J White
P2860
P356
10.1017/S1462399409001021
P577
2009-03-23T00:00:00Z